The establishment of HLRCC patient-derived renal cell line models that recapitulate the metabolic alterations observed in FH-deficient tumors has provided a valuable tool for delineating critical vulnerabilities in FH-deficient tumors14,24–26. Here, FH is linked to hereditary leiomyomatosis and renal cell cancer.